Kenvue Shares Drop as RFK Jr. Plans Tylenol Autism Link Report

Shares of Kenvue, the maker of Tylenol, fell sharply following reports that Health and Human Services Secretary Robert F. Kennedy Jr. plans to release a report this month linking prenatal acetaminophen exposure to autism spectrum disorder (ASD). The proposed report is part of Kennedy's broader effort to identify environmental causes of the rising autism rates in the U.S., which have increased significantly over the past two decades. Despite the report's claims, Kenvue strongly disputes any causal connection between acetaminophen use during pregnancy and autism, emphasizing its commitment to product safety and advising pregnant women to consult healthcare professionals. Analysts have reacted with mixed sentiments, reflecting a cautious outlook on Kenvue’s stock, though some see potential upside despite recent declines. The controversy comes amid Kennedy’s ongoing research initiative, which has faced skepticism about the feasibility of drawing definitive conclusions within the stated timeline. Overall, the developing news has created market uncertainty for Kenvue while spotlighting public health debates around common medications and autism risk factors.